AstraZeneca is advancing understanding of cardio-renal-metabolic interconnectivity with new evidence at ESC 2018

New evidence of the persistency of ischaemic risk in post-heart attack patients, highlighting specific risk factors that may help identify patients for extended DAPT

Latest data on the links between RAAS inhibitor dose reduction and increased risk of mortality and MACE in heart failure patients with hyperkalaemia

First Phase IIa trial results on MEDI6012 in atherosclerosis, demonstrating cardio-protective potential

AstraZeneca and MedImmune, its global biologics research and development arm, will present new data from its Cardiovascular, Renal and Metabolism (CVRM) portfolio of medicines at the European Society of Cardiology (ESC) Congress in Munich, Germany, 25-29 August 2018, aiming to help inform clinical practice for the treatment of patients with overlapping CVRM diseases and multiple risk factors.

Highlights will include:

·        New real-world evidence on patients most at risk of future cardiovascular events, including death, underlining the need for improved secondary prevention including dual antiplatelet therapy (DAPT). The latest research also aims to inform clinical practice in patients with type-2 diabetes treated with glucose-lowering drugs who may also have coronary artery disease and/or experienced a prior heart attack or stroke

·        Evaluation of real-world consequences in sub-optimal renal-angiotensin-aldosterone system (RAAS) inhibitor dosing in the treatment of heart failure patients with hyperkalaemia, aiming to ensure patients receive optimum cardio-renal protection

·        Phase IIa results from the first collaboration between MedImmune and TIMI Study Group indicate the potential therapeutic benefit of MEDI6012, a lecithin-cholesterol acyltransferase (LCAT), for the treatment of atherosclerosis in patients having experienced the most serious type of heart attack

Ludovic Helfgott, Vice President, Cardiovascular, Renal and Metabolism at AstraZeneca, said: “At ESC, we continue to explore the intricacies of cardio-renal and metabolic risk with our determination to improve patient outcomes. The data to be presented in Munich this year underscores the persistent ischaemic risk in patients with additional risk factors such as diabetes or multi-vessel disease, and demonstrates clinical benefits in heart failure for patients with hyperkalaemia.”

Increased and persistent ischaemic risk in patients with additional risk factors

·        PRECLUDE-2 is an analysis of >100,000 heart attack (myocardial infarction) patients treated with percutaneous coronary intervention (PCI) from the SWEDEHEART registry, examining the additive effects of risk factors (diabetes, renal impairment, age≥65yrs, multi-vessel disease, further heart attacks) on the risk of subsequent ischaemic events and major bleeding events. [Presentation: #1398. Sunday 26 August, 11:18 – 11:35 CEST at Spotlight Village]

·        TIGRIS is a global prospective registry study to evaluate clinical management, quality of life and outcomes during a two-year follow-up in high-risk patients with stable coronary artery disease (CAD), one to three years post-myocardial infarction (MI). [Presentation: #5261. Tuesday 28 August, 11:52 – 12:05 CEST at Spotlight Village]

·        ATHENA is a Swedish nationwide registry study designed to compare cardiovascular risk in type-2 diabetes patients with any of: a prior MI or stroke; CAD but without prior MI or stroke; or without CAD, prior MI or stroke. [Presentation: #P6425. Sunday 26 August, 14:00 – 18:00 CEST at Poster Area]

Maintaining treatment benefit in heart failure patients with hyperkalaemia

·        Results from two real-world studies assessing the impact of RAAS inhibition in heart failure patients with hyperkalaemia:

o   Investigating RAAS inhibitor dosing in heart failure patients including the association between hyperkalaemia and down-titration/discontinuation of RAAS inhibitor therapies. [Presentation: #P1810. Sunday 26 August, 8:30 – 12:30 CEST at Poster Area]

o   The association between RAAS inhibitor dosing and the risk of mortality and major adverse cardiovascular events (MACE) in heart failure patients. [Presentation: #P5671. Tuesday 28 August, 8:30 – 12:30 CEST at Poster Area]

Advancing the cardiology pipeline

·        Phase IIa results from a trial investigating MEDI6012 recombinant LCAT in patients with stable atherosclerosis to assess safety and efficacy; this represents the first findings from a new collaboration between MedImmune and the TIMI Study Group. [Presentation: #354. Saturday 25 August, 13:30 – 15:00 CEST at Agora1]

Details of further key abstracts from AstraZeneca/MedImmune: (all times are CEST)

 

Abstract title

Presentation details

Multiple biomarkers and cause-specific mortality in patients with acute coronary syndromes - Insights from the PLATO biomarker substudy

#P823 Saturday 25 August, 11:00 – 16:00 at Poster Area

Atheroprotective effects of ticagrelor, a P2Y12 antagonist, in apolipoprotein-E-deficient mice

#P3784 Saturday 25 August, 11:00 – 16:00 at Poster Area

Perceived or calculated bleeding risk in patients undergoing percutaneous coronary intervention: inside the post-PCI prospective registry

#2227 Sunday 26 August, 14:30 – 14:47
at Science Box 1 – Poster Area

Are perceived or calculated bleeding risk related to DAPT choice in patients undergoing percutaneous coronary intervention?

#2228 Sunday 26 August, 14:48 – 15:05
at Science Box 1 - Poster Area

Effects of ticagrelor vs. clopidogrel on neointimal proliferation in paclitaxel-eluting stents implanted in the femoropopliteal district: a randomized pilot study using optical coherence tomography

#P2771 Sunday 26 August, 14:00 – 18:00
at Poster Area

 

Atrial reservoir function is related to coronary flow reserve in patients with stable coronary artery disease

#P1710 Sunday 26 August, 8:30 – 12:30
at Poster Area

Global Leaders Trial - A randomized comparison of 24 month ticagrelor and 1 month aspirin versus 12 month dual antiplatelet therapy followed by aspirin monotherapy

#3224 Sunday 26 August, 12:08
at Main Auditorium

Acute and chronic effect of ticagrelor versus clopidogrel on aortic stiffness

#P2291 Sunday 26 August, 15:50 – 16:40 at Poster Area

Moderate to severe renal insufficiency and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial

#4065 Monday 27 August, 14:58 – 15:07
at Agora 2

Impaired fibrin clot lysis persists at 1 month post ACS: a PLATO substudy

#P4404 Monday 27 August, 14:00 – 18:00 at Poster Area

Ticagrelor potentiates the cardioprotective effects of remote ischemic preconditioning

#P5506 Tuesday 28 August, 8:30 – 12:30 at Poster Area

Effects of once-weekly exenatide on clinical outcomes in the subgroup of patients with pre-existing cardiovascular disease: Insights from EXSCEL

#P5257 Tuesday 28 August, 11:00 – 12:30 at Spotlight Village

Influence of intravenous fentanyl versus morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary PCI

#5918 Tuesday 28 August, 15:23 – 15:33
at Agora 1

ENDS

 

NOTES TO EDITORS

About AstraZeneca in Cardiovascular, Renal & Metabolism (CVRM)

Cardiovascular, renal and metabolic diseases together form one of AstraZeneca’s main therapy areas and platforms for future growth. By following the science to understand more clearly the underlying links between the heart, kidney and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling co-morbidities. Our ambition is to modify or halt the natural course of CVRM diseases and even regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of patients worldwide.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

 

Media Relations

 

 

Karen Birmingham

UK/Global

+44 203 749 5634

Rob Skelding

UK/Global

+44 203 749 5821

Matt Kent

UK/Global

+44 203 749 5906

Gonzalo Viña

UK/Global

+44 203 749 5916

Jacob Lund

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677

 

 

 

Investor Relations

 

 

Thomas Kudsk Larsen

 

 

+44 203 749 5712

Josie Afolabi

 

+44 203 749 5631

Craig Marks

Finance; Fixed Income

+44 7881 615 764

Henry Wheeler

Oncology

+44 203 749 5797

Mitchell Chan

Oncology; Other

+1 240 477 3771

Christer Gruvris

Cardiovascular; Metabolism

+44 203 749 5711

Nick Stone

Respiratory; Renal

+44 203 749 5716

Jennifer Kretzmann

Retail Investors

+44 203 749 5824

US toll-free

 

+1 866 381 7277